Literature DB >> 16135656

CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.

Hiroyuki Yamanaka1, Miki Nakajima, Tatsuki Fukami, Haruko Sakai, Akiko Nakamura, Miki Katoh, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi.   

Abstract

Nornicotine is an N-demethylated metabolite of nicotine. In the present study, human cytochrome P450 (P450) isoform(s) involved in nicotine N-demethylation were identified. The Eadie-Hofstee plot of nicotine N-demethylation in human liver microsomes was biphasic with high-affinity (apparent K(m) = 173 +/- 70 microM, V(max) = 57 +/- 17 pmol/min/mg) and low-affinity (apparent K(m) = 619 +/- 68 microM, V(max) = 137 +/- 6 pmol/min/mg) components. Among 13 recombinant human P450s expressed in baculovirus-infected insect cells (Supersomes), CYP2B6 exhibited the highest nicotine N-demethylase activity, followed by CYP2A6. The apparent K(m) values of CYP2A6 (49 +/- 12 microM) and CYP2B6 (550 +/- 46 microM) were close to those of high- and low-affinity components in human liver microsomes, respectively. The intrinsic clearances of CYP2A6 and CYP2B6 Supersomes were 5.1 and 12.5 nl/min/pmol P450, respectively. In addition, the intrinsic clearance of CYP2A13 expressed in Escherichia coli (44.9 nl/min/pmol P450) was higher than that of CYP2A6 expressed in E. coli (2.6 nl/min/pmol P450). Since CYP2A13 is hardly expressed in human livers, the contribution of CYP2A13 to the nicotine N-demethylation in human liver microsomes would be negligible. The nicotine N-demethylase activity in microsomes from 15 human livers at 20 microM nicotine was significantly correlated with the CYP2A6 contents (r = 0.578, p < 0.05), coumarin 7-hydroxylase activity (r = 0.802, p < 0.001), and S-mephenytoin N-demethylase activity (r = 0.694, p < 0.005). The nicotine N-demethylase activity at 100 microM nicotine was significantly correlated with the CYP2B6 contents (r = 0.677, p < 0.05) and S-mephenytoin N-demethylase activities (r = 0.740, p < 0.005). These results as well as the inhibition analyses suggested that CYP2A6 and CYP2B6 would significantly contribute to the nicotine N-demethylation at low and high substrate concentrations, respectively. The contributions of CYP2A6 and CYP2B6 would be dependent on the expression levels of these isoforms in any human liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135656     DOI: 10.1124/dmd.105.006254

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 2.  Pharmacotherapy for smoking cessation: current advances and research topics.

Authors:  Tobias Raupach; Constant P van Schayck
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

3.  Brain CYP2B induction can decrease nicotine levels in the brain.

Authors:  Kristine L P Garcia; Anh Dzung Lê; Rachel F Tyndale
Journal:  Addict Biol       Date:  2016-05-27       Impact factor: 4.280

Review 4.  Tobacco use and cessation among women: research and treatment-related issues.

Authors:  Shiva D Rahmanian; Philip T Diaz; Mary Ellen Wewers
Journal:  J Womens Health (Larchmt)       Date:  2011-03       Impact factor: 2.681

5.  Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.

Authors:  Evelyn L Craig; Bin Zhao; Jason Z Cui; Maria Novalen; Sharon Miksys; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-06-30       Impact factor: 3.922

6.  Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain.

Authors:  Geeta Sharma; Sukumar Vijayaraghavan
Journal:  Subst Abuse       Date:  2008-11-11

7.  Enantioselective demethylation of nicotine as a mechanism for variable nornicotine composition in tobacco leaf.

Authors:  Bin Cai; Balazs Siminszky; Joseph Chappell; Ralph E Dewey; Lowell P Bush
Journal:  J Biol Chem       Date:  2012-10-25       Impact factor: 5.157

8.  Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

Authors:  Sean P David; Richard A Brown; George D Papandonatos; Christopher W Kahler; Elizabeth E Lloyd-Richardson; Marcus R Munafò; Peter G Shields; Caryn Lerman; David Strong; Jeanne McCaffery; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2007-08       Impact factor: 4.244

9.  Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways.

Authors:  Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2017-11-20       Impact factor: 4.030

10.  Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma.

Authors:  Paula L Vieira-Brock; David M Andrenyak; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  Nicotine Tob Res       Date:  2013-06-04       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.